[go: up one dir, main page]

NO20006462L - Anvendelse av fumarsyrederivater i transplantasjonsmedisin - Google Patents

Anvendelse av fumarsyrederivater i transplantasjonsmedisin

Info

Publication number
NO20006462L
NO20006462L NO20006462A NO20006462A NO20006462L NO 20006462 L NO20006462 L NO 20006462L NO 20006462 A NO20006462 A NO 20006462A NO 20006462 A NO20006462 A NO 20006462A NO 20006462 L NO20006462 L NO 20006462L
Authority
NO
Norway
Prior art keywords
fumaric acid
acid derivatives
transplant medicine
combination
monoalkyl esters
Prior art date
Application number
NO20006462A
Other languages
English (en)
Norwegian (no)
Other versions
NO20006462D0 (no
Inventor
Rajendra Kumar Joshi
Hans-Peter Strebel
Original Assignee
Fumapharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fumapharm Ag filed Critical Fumapharm Ag
Publication of NO20006462D0 publication Critical patent/NO20006462D0/no
Publication of NO20006462L publication Critical patent/NO20006462L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20006462A 1998-08-31 2000-12-18 Anvendelse av fumarsyrederivater i transplantasjonsmedisin NO20006462L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19839566A DE19839566C2 (de) 1998-08-31 1998-08-31 Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
PCT/EP1999/006110 WO2000012072A2 (de) 1998-08-31 1999-08-20 Verwendung von fumarsäurederivaten in der transplantationsmedizin

Publications (2)

Publication Number Publication Date
NO20006462D0 NO20006462D0 (no) 2000-12-18
NO20006462L true NO20006462L (no) 2001-04-30

Family

ID=7879272

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006462A NO20006462L (no) 1998-08-31 2000-12-18 Anvendelse av fumarsyrederivater i transplantasjonsmedisin

Country Status (25)

Country Link
US (1) US6359003B1 (et)
EP (1) EP1107749B1 (et)
JP (1) JP3553883B2 (et)
CN (1) CN1195511C (et)
AT (1) ATE241353T1 (et)
AU (1) AU746958B2 (et)
BG (1) BG64435B1 (et)
BR (1) BR9908722A (et)
CA (1) CA2322188C (et)
DE (2) DE19839566C2 (et)
DK (1) DK1107749T3 (et)
EE (1) EE05025B1 (et)
ES (1) ES2195609T3 (et)
HK (1) HK1040623B (et)
HU (1) HUP0101854A3 (et)
IL (1) IL138110A0 (et)
NO (1) NO20006462L (et)
NZ (1) NZ506573A (et)
PL (1) PL198211B1 (et)
PT (1) PT1107749E (et)
RS (1) RS49780B (et)
RU (1) RU2210364C2 (et)
SK (1) SK286352B6 (et)
TR (1) TR200002475T2 (et)
WO (1) WO2000012072A2 (et)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
US6342294B1 (en) 1999-08-12 2002-01-29 Bruce G. Ruefer Composite PTFE article and method of manufacture
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
RU2290946C2 (ru) * 2001-01-12 2007-01-10 Фумафарм Аг Амиды фумаровой кислоты
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
DE10217314A1 (de) 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
AU2003236156A1 (en) * 2003-04-24 2005-01-04 Shin-Jen Shiao Pharmaceutical compositions used for immune disease treatment and improvement
DK1663197T3 (da) * 2003-09-09 2008-01-07 Fumapharm Ag Anvendelse af fumarsyrederivater til behandling af hjerteinsuffiens og astma
DE10360869A1 (de) * 2003-09-09 2005-04-07 Fumapharm Ag Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma
ES2582942T3 (es) * 2004-10-08 2016-09-16 Forward Pharma A/S Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
US20100144651A1 (en) * 2005-07-07 2010-06-10 Aditech Pharma Ab Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use
EP1915334A2 (en) * 2005-07-07 2008-04-30 Aditech Pharma AB Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
WO2007042035A2 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
WO2007042034A1 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
ES2599227T3 (es) * 2007-02-08 2017-01-31 Biogen Ma Inc. Neuroprotección en enfermedades desmielinizantes
SI2653873T1 (sl) 2007-02-08 2022-09-30 Biogen Ma Inc. Sestave in načini uporabe za zdravljenje multiple skleroze
WO2009078754A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances
US8148414B2 (en) 2008-08-19 2012-04-03 Xenoport, Inc. Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
HUE030169T2 (en) 2009-01-09 2017-05-29 Forward Pharma As Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
HUE036085T2 (hu) 2011-06-08 2018-06-28 Biogen Ma Inc Nagy tisztaságú és kristályos dimetil-fumarát elõállítására szolgáló eljárás
BR112014002407A2 (pt) * 2011-08-30 2017-02-21 Toyama Chemical Co Ltd método para melhorar a terapia contra doenças autoimunes tais como artrite reumatóide
EP2782561A1 (en) 2011-11-24 2014-10-01 Synthon BV Controlled release particles comprising dimethyl fumarate
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
CN113244185A (zh) 2012-02-07 2021-08-13 比奥根玛公司 含有富马酸二甲酯的药物组合物
KR20140129136A (ko) 2012-02-07 2014-11-06 제노포트 인코포레이티드 모르폴리노알킬 푸마레이트 화합물, 약제학적 조성물 및 사용 방법
AU2013305684B2 (en) 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
WO2014031901A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of use for monomethyl fumarate and prodrugs thereof
WO2014031844A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
CN103483194B (zh) * 2012-11-30 2016-03-09 杨寅柯 一种2-氟代富马酸酯(结构式i)及其制备方法及应用
AR094277A1 (es) 2012-12-21 2015-07-22 Biogen Idec Inc Derivados de fumarato sustituidos con deuterio
PT2970101T (pt) 2013-03-14 2018-10-04 Alkermes Pharma Ireland Ltd Pró-fármacos de fumaratos e seu uso no tratamento de várias doenças
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
EP3041467A1 (en) 2013-09-06 2016-07-13 XenoPort, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
AU2015218587B2 (en) 2014-02-24 2017-04-27 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
SG11201705124QA (en) 2015-02-08 2017-07-28 Alkermes Pharma Ireland Ltd Monomethylfumarate prodrug compositions
DK3273951T3 (da) 2015-03-27 2020-11-02 Symbionyx Pharmaceuticals Inc Sammensætninger og fremgangsmåder til behandling af psoriasis
WO2017060400A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
CN106265621B (zh) * 2016-09-19 2019-05-17 苏州大学 富马酸二甲酯在制备预防和治疗移植物抗宿主病及移植物抗白血病药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530372A1 (de) * 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2621214C3 (de) * 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
CH664150A5 (de) * 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
US5149695A (en) * 1985-01-15 1992-09-22 Speiser Peter P Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
US5424332A (en) * 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
MC1999A1 (fr) * 1987-12-18 1990-01-26 Hoffmann La Roche Composes tricycliques
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
WO1998004290A2 (en) 1996-07-26 1998-02-05 Perrine Susan P Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders
AU5474198A (en) 1996-12-24 1998-07-17 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19814358C2 (de) * 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn

Also Published As

Publication number Publication date
US6359003B1 (en) 2002-03-19
HUP0101854A3 (en) 2003-04-28
SK286352B6 (en) 2008-07-07
PL198211B1 (pl) 2008-06-30
SK2572001A3 (en) 2002-05-09
CA2322188A1 (en) 2000-03-09
HK1040623A1 (en) 2002-06-21
BG104679A (en) 2001-02-28
CA2322188C (en) 2004-03-09
WO2000012072A2 (de) 2000-03-09
IL138110A0 (en) 2001-10-31
EP1107749A2 (de) 2001-06-20
EE05025B1 (et) 2008-06-16
PL347359A1 (en) 2002-04-08
NZ506573A (en) 2002-10-25
JP3553883B2 (ja) 2004-08-11
CN1195511C (zh) 2005-04-06
DK1107749T3 (da) 2003-08-18
ATE241353T1 (de) 2003-06-15
NO20006462D0 (no) 2000-12-18
BR9908722A (pt) 2001-10-16
HK1040623B (zh) 2005-08-19
JP2002525276A (ja) 2002-08-13
WO2000012072A3 (de) 2000-05-04
RU2210364C2 (ru) 2003-08-20
BG64435B1 (en) 2005-02-28
PT1107749E (pt) 2003-08-29
DE59905763D1 (de) 2003-07-03
ES2195609T3 (es) 2003-12-01
HUP0101854A2 (hu) 2001-11-28
DE19839566C2 (de) 2002-01-17
EP1107749B1 (de) 2003-05-28
AU5737899A (en) 2000-03-21
TR200002475T2 (tr) 2001-03-21
DE19839566A1 (de) 2000-03-09
YU58800A (sh) 2002-03-18
CN1316901A (zh) 2001-10-10
AU746958B2 (en) 2002-05-09
RS49780B (sr) 2008-06-05
EE200000654A (et) 2002-04-15

Similar Documents

Publication Publication Date Title
NO20006462L (no) Anvendelse av fumarsyrederivater i transplantasjonsmedisin
DE59905954D1 (de) Dialkylfumarate zur behandlung von autoimmunerkrankungen
TR200102648T2 (tr) Büyümeyi destekleyen bileşimler
ATE257386T1 (de) Pharmazeutische zusammensetzungen enthaltend eine mischung von selbstvernetzter und nichtselbstvernetzter hyaluronsäure zur behandlung von arthropathien
NO308794B1 (no) Farmakologisk aktive pyridin-derivater, preparater inneholdende forbindelsene samt forbindelsenes anvendelse
DE59807122D1 (de) Verwendung von fumarsäurederivaten zur behandlung von autoimmunerkrankungen
DE60041976D1 (de) Phenoxycarbonsäureverbindungen und zusammensetzungen zur verabreichung aktiver wirkstoffe
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
DE69832710D1 (de) Nicht-irritierende zusammensetzung zur behandlung des aknes und andere hautzustände
BG103096A (en) Thrombin inhibitors
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
ATE90563T1 (de) Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application